Immucell CORP: directors' dealings · United States · SEC (Form 4)

About Immucell CORP

ImmuCell Corp /DE/ (ticker: ICCC) is a Nasdaq-listed company in the United States focused on animal health and, more specifically, biologics for calves. Founded in 1982 and taken public in 1987, the company shifted its strategic emphasis in the late 1990s toward dairy and beef applications after obtaining USDA approval to market First Defense® in 1991. Its headquarters are in Portland, Maine. ImmuCell remains a niche operator rather than a broad-based animal-health platform, with a portfolio centered on a few core products and a strong technical specialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/811641/000121390016011870/f10k2015_immucellcorp.htm?utm_source=openai)) The company’s main business is the development, manufacturing, and commercialization of the First Defense® line, designed to provide immediate immune protection to newborn dairy and beef calves against scours (neonatal calf diarrhea). Management positions this condition as a major economic burden for the U.S. cattle industry and frames First Defense as a biologic, USDA-licensed scours-prevention franchise. ImmuCell also continues to develop Re-Tain®, a treatment candidate for subclinical mastitis in lactating dairy cows, although this program has experienced regulatory and accounting-related setbacks, including recent asset write-downs. ([immucell.com](https://immucell.com/investors/)) From a competitive standpoint, ImmuCell’s differentiation comes from proprietary biologic know-how and its scale in hyperimmunized bovine colostrum processing. The company states that it is the only animal-health company able to hyperimmunize bovine colostrum commercially, which supports its positioning in a specialized, high-barrier niche. Rather than competing as a diversified animal-health conglomerate, ImmuCell competes on product efficacy, manufacturing capability, and on-farm economic value. Its market exposure is primarily tied to North American dairy and beef production, where adoption is driven by calf survival, productivity, and reduced dependence on antibiotics. ([immucell.com](https://immucell.com/about-immucell/our-purpose/?utm_source=openai)) Recent developments suggest a meaningful operational improvement. In its March 2026 release covering full-year 2025 results, ImmuCell reported product sales of approximately $27.6 million, up 4.3% year over year, gross margin of 41.4% versus 30.0% in 2024, and net operating income of $1.6 million. Management attributed the improvement to higher volumes, better manufacturing efficiency, and improved price realization, while also noting one-time items linked to Re-Tain® and CEO transition costs. The company also highlighted an increase in average monthly output and a continued focus on yield improvement. For investors, ICCC is a small-cap Nasdaq animal-health story in the United States with a focused product set, a defensible niche, and a profile that depends heavily on execution in manufacturing, commercialization, and regulatory development. ([immucell.com](https://immucell.com/wp-content/investor-assets/press-releases/2026/Rel2026-03-04-lttrhead.pdf))